Modulation of bone turnover by glucocorticoid treatment
M. Scheinost; K. Pavelka
Revmatologický ústav Praha
Čes. Revmatol., 14, 2006, No. 1, p. 9-16.
Osteoporosis is a chronic disabling disease, which, due to its asymptomatic onset, is frequently initially neglected. Secondary prevention of this metabolic disorder is not even common in the outpatient offices of specialists. Only one from five osteoporotic fractures is treated. Osteoporosis is misinterpreted as a disease of elderly but according to statistical data from the International osteoporosis foundation (IOF), one of two women and one of eight men 50 years old suffer from osteoporosis. Femoral neck fracture mortality in these women is similar to the breast cancer patients. It is necessary to mention economic aspects as well. While the prevalence of osteoporosis in the Czech Republic is 750 thousands patients, the pharmacotherapy costs approximate 7.5 billion Czech crowns per year and similar sum is spent for surgical managements and peri-operative period of osteoporotic fractures. All abovementioned statistics are alarming, particularly given the fact that population tends to be older. Glucocorticoid-induced loss of bone is the most frequent secondary osteoporosis owing to their widespread use. According to the recent studies, there is no safe dose of glucocorticoids that can avoid adverse events. The authors discuss here pathogenetic mechanisms of glucocorticoid-induced osteoporosis. An issue that is going to be under close scientific investigation in the near future is outlined at the end of this article. Then, particular guidelines postulated by professional associations could enforce rational prevention and specific treatment that are considered to control glucocorticoid-induced osteoporosis – the disease with high morbidity, common social isolation of the patients, and, last but not least, astronomical economic consequences.
osteoporosis, glucocorticoids, osteoblasts
Dermatology & STDs